GT201500292A - Formas cristalinas de inhibidores de tirosina cinasa y sus sales - Google Patents
Formas cristalinas de inhibidores de tirosina cinasa y sus salesInfo
- Publication number
- GT201500292A GT201500292A GT201500292A GT201500292A GT201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A GT 201500292 A GT201500292 A GT 201500292A
- Authority
- GT
- Guatemala
- Prior art keywords
- salts
- tyrosine kinase
- kinase inhibitors
- crystalline forms
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A VARIAS FORMAS POLIMÓRFICAS Y FORMA AMORFA DE 4-((3-(4-CICLOHEXILPIPERAZIN-1-IL)-6-OXO-6H-ANTRAL[1, 9 -CD] ISOXAZOL-5-IL)AMMINO)BENZATO DE SODIO, QUE INCLUYE LA FORMA POLIMÓRFICA A, MEZCLAS DE LOS POLIMORFOS, PROCESOS PARA LA PREPARACIÓN DE LOS MISMOS Y EL USO DE LOS MISMOS EN UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE A LOS MISMOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361801112P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201500292A true GT201500292A (es) | 2019-07-29 |
Family
ID=51529961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201500292A GT201500292A (es) | 2013-03-15 | 2015-09-14 | Formas cristalinas de inhibidores de tirosina cinasa y sus sales |
Country Status (23)
Country | Link |
---|---|
US (5) | US8999992B2 (es) |
EP (1) | EP2970148A4 (es) |
JP (1) | JP2016513704A (es) |
KR (1) | KR20150142688A (es) |
CN (1) | CN105377821A (es) |
AU (1) | AU2014239254B2 (es) |
BR (1) | BR112015022631A2 (es) |
CA (1) | CA2904403A1 (es) |
CL (1) | CL2015002593A1 (es) |
CR (1) | CR20150560A (es) |
EA (1) | EA201591684A1 (es) |
GT (1) | GT201500292A (es) |
HK (1) | HK1220193A1 (es) |
MX (1) | MX2015012403A (es) |
NI (1) | NI201500139A (es) |
PE (1) | PE20151884A1 (es) |
PH (1) | PH12015502110A1 (es) |
SG (2) | SG10201707484UA (es) |
SV (1) | SV2015005074A (es) |
TN (1) | TN2015000407A1 (es) |
UA (1) | UA116466C2 (es) |
WO (1) | WO2014152663A1 (es) |
ZA (1) | ZA201507154B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
US8999992B2 (en) * | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
CA2962206A1 (en) * | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
WO2017027465A1 (en) * | 2015-08-07 | 2017-02-16 | Purdue Pharma L.P. | Process of preparing tyrosine kinase inhibitor |
HUE056615T2 (hu) | 2017-10-18 | 2022-02-28 | Incyte Corp | Tercier hidroxicsoportokkal szubsztituált kondenzált imidazol-származékok mint PI3K-gamma inhibitorok |
WO2019159097A1 (en) * | 2018-02-14 | 2019-08-22 | Sun Pharmaceutical Industries Limited | Crystalline polymorphic forms of acalabrutinib |
WO2020051169A1 (en) | 2018-09-05 | 2020-03-12 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1062357A (en) * | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US4337341A (en) * | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
RU2065438C1 (ru) | 1993-12-22 | 1996-08-20 | Институт химии природного органического сырья СО РАН | Способ получения производных 3-фенилокси-5-гидроксиантра (1,9-cd)-изоксазол-6-она |
US6635626B1 (en) | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US5998463A (en) | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
US6476032B2 (en) | 1998-12-17 | 2002-11-05 | Wyeth | 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5(6H)one derivatives |
CN1636005A (zh) | 1999-06-03 | 2005-07-06 | 克诺尔股份有限公司 | 苯并噻嗪酮和苯并噁嗪酮化合物 |
FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
JP2005508337A (ja) | 2001-09-27 | 2005-03-31 | スミスクライン ビーチャム コーポレーション | 化合物 |
KR20030095729A (ko) | 2002-06-14 | 2003-12-24 | 크리스탈지노믹스(주) | 2-[5-(3-카복시-4-클로로-페닐)-푸란-2-일메틸렌]-3-옥소-2,3-디하이드로-5H-티아졸로[3,2-a]피리미딘-6-카복실산에틸 에스테르 유도체를 포함하는 단백질 티로신포스파타제 1B 활성 억제용 약학 조성물 |
WO2004032870A2 (en) | 2002-10-08 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
EP2033654B1 (en) | 2003-04-16 | 2012-05-16 | Bristol-Myers Squibb Company | Process for resolving a mixture of alkyl ester enantiomers using an enzyme |
WO2005020897A2 (en) | 2003-08-22 | 2005-03-10 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with trp-p8 expression |
WO2008021463A2 (en) | 2006-08-15 | 2008-02-21 | Acadia Pharmaceuticals, Inc. | Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders |
SI1732949T1 (sl) | 2004-04-07 | 2010-05-31 | Rinat Neuroscience Corp | Postopki za zdravljenje bolečine kostnega raka zdajanjem antagonista živčnega rastnega faktorja |
WO2006007864A1 (en) | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
US7671077B2 (en) * | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
FR2881138B1 (fr) | 2005-01-27 | 2007-03-02 | Servier Lab | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
JP5191155B2 (ja) | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
JP2007303392A (ja) | 2006-05-11 | 2007-11-22 | Honda Motor Co Ltd | 気体燃料内燃機関の制御装置 |
WO2008053863A1 (fr) | 2006-10-30 | 2008-05-08 | Santen Pharmaceutical Co., Ltd. | Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one |
JP5496680B2 (ja) | 2006-12-28 | 2014-05-21 | アッヴィ・インコーポレイテッド | ポリ(adp−リボース)ポリメラーゼの阻害剤 |
WO2009024989A2 (en) | 2007-08-17 | 2009-02-26 | Hetero Drugs Limited | A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
WO2009067197A2 (en) | 2007-11-16 | 2009-05-28 | Rayspan Corporation | Filter design methods and filters based on metamaterial structures |
US9040508B2 (en) | 2008-12-08 | 2015-05-26 | Vm Pharma Llc | Compositions of protein receptor tyrosine kinase inhibitors |
EP2239256A1 (en) * | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
CA2796192A1 (en) | 2010-06-23 | 2011-12-29 | OSI Pharmaceuticals, LLC | Polymorphs of osi-906 |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
US9376406B2 (en) | 2011-03-03 | 2016-06-28 | Indiana University Research And Technology Corporation | uPAR-uPA interaction inhibitors and methods for treating cancer |
US8999992B2 (en) | 2013-03-15 | 2015-04-07 | Vm Pharma Llc | Crystalline forms of tryosine kinase inhibitors and their salts |
CA2962206A1 (en) | 2014-09-17 | 2016-03-24 | Mundipharma International Corporation Limited | Crystalline forms of tyrosine kinase inhibitors and their salts |
-
2014
- 2014-03-13 US US14/208,244 patent/US8999992B2/en active Active
- 2014-03-14 KR KR1020157029442A patent/KR20150142688A/ko not_active Application Discontinuation
- 2014-03-14 AU AU2014239254A patent/AU2014239254B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14770743.4A patent/EP2970148A4/en not_active Withdrawn
- 2014-03-14 EA EA201591684A patent/EA201591684A1/ru unknown
- 2014-03-14 JP JP2016502487A patent/JP2016513704A/ja active Pending
- 2014-03-14 BR BR112015022631A patent/BR112015022631A2/pt not_active IP Right Cessation
- 2014-03-14 CA CA2904403A patent/CA2904403A1/en not_active Abandoned
- 2014-03-14 CR CR20150560A patent/CR20150560A/es unknown
- 2014-03-14 MX MX2015012403A patent/MX2015012403A/es unknown
- 2014-03-14 SG SG10201707484UA patent/SG10201707484UA/en unknown
- 2014-03-14 CN CN201480015906.9A patent/CN105377821A/zh active Pending
- 2014-03-14 WO PCT/US2014/027591 patent/WO2014152663A1/en active Application Filing
- 2014-03-14 UA UAA201509781A patent/UA116466C2/uk unknown
- 2014-03-14 SG SG11201507516XA patent/SG11201507516XA/en unknown
- 2014-03-14 US US14/772,264 patent/US9718794B2/en active Active
- 2014-03-14 PE PE2015002014A patent/PE20151884A1/es not_active Application Discontinuation
-
2015
- 2015-03-02 US US14/635,635 patent/US9388146B2/en active Active
- 2015-09-10 TN TN2015000407A patent/TN2015000407A1/en unknown
- 2015-09-10 CL CL2015002593A patent/CL2015002593A1/es unknown
- 2015-09-11 NI NI201500139A patent/NI201500139A/es unknown
- 2015-09-14 GT GT201500292A patent/GT201500292A/es unknown
- 2015-09-14 PH PH12015502110A patent/PH12015502110A1/en unknown
- 2015-09-14 SV SV2015005074A patent/SV2015005074A/es unknown
- 2015-09-28 ZA ZA2015/07154A patent/ZA201507154B/en unknown
-
2016
- 2016-06-17 US US15/185,754 patent/US9993473B2/en active Active
- 2016-07-14 HK HK16108270.6A patent/HK1220193A1/zh unknown
-
2017
- 2017-07-13 US US15/648,527 patent/US10124002B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201500292A (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
CR20150629A (es) | Compuestos químicos | |
CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
CY1122222T1 (el) | Συνθεση βορονικων αλατων και χρησεις αυτων | |
ECSP18092481A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
CR20160099A (es) | Formulación de inhibidores de la syk | |
DOP2015000196A (es) | Amidas heterocíclicas como inhibidores de cinasas | |
BR112018015880A2 (pt) | forma cristalina a de agonista de tlr7, método de preparação e uso da mesma | |
GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
NI201500096A (es) | Compuesto químicos | |
DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
DK3003038T3 (da) | 2h-1,2,3-triazolderivater som inhibitorer af fibrose | |
DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
ECSP16074478A (es) | Compuestos novedosos | |
CR20160400A (es) | Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza | |
UY36166A (es) | Formas de sales de n—(cianometil)—4—(2—(4—morfolinofenilamino)pirimidin—4—il)benzamida, sus composiciones y su uso terapeutico | |
CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
CL2016001172A1 (es) | Nuevos inhibidores de dgat2. | |
CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
CR20160016A (es) | Pirazolpiridinas sustituidas | |
DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
CR20160494A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
EA201600123A1 (ru) | Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона |